Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, William Jacot et al.|New England Journal of Medicine|2022Cited by 2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerAleix Prat, Charles M. Perou, Joel S. Parker et al.|Breast Cancer Research|2010Cited by 2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Fátima Cardoso, E.P. Winer, Elżbieta Senkus et al.|Annals of Oncology|2018Cited by 1.2k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Suzette Delaloge et al.|Annals of Oncology|2021Cited by 799
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionYasir H. Ibrahim, José Baselga, Celina García-García et al.|Cancer Discovery|2012Cited by 622